Communiqué de presse : Sanofi va acquérir Dynavax et ajouter un vaccin commercialisé contre l’hépatite B pour adultes et un candidat vaccin de phase 1⁄2 contre le zona au pipeline
View original at globenewswire.comCommuniqué de presse : Sanofi va acquérir Dynavax et ajouter un vaccin commercialisé contre l’hépatite B pour adultes et un candidat vaccin de phase 1⁄2 contre le zona au pipeline Sanofi va acquérir Dynavax et ajouter un vaccin commercialisé contre l’hépatite B pour adultes et un candidat vaccin de phase 1⁄2 contre le…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
Shingles affects one in three adults during their lifetime
80% confidenceDynavax strengthens Sanofi's presence in adult vaccination by bringing differentiated vaccines that complement Sanofi's expertise
80% confidenceSanofi's commercial presence, development capabilities and vision of science-based immunization will amplify opportunities for HEPLISAV-B and innovative pipeline to meet important public health needs
80% confidenceThe marketed adult hepatitis B vaccine and shingles vaccine candidate add new options to Sanofi's portfolio and underscore commitment to providing vaccine protection throughout life
80% confidenceJoining Sanofi will bring the global scale and expertise needed to maximize the impact of Dynavax's vaccine portfolio
80% confidenceThe acquisition is expected to close in Q1 2026, subject to satisfaction or waiver of customary closing conditions
80% confidenceThe Dynavax acquisition agreement should not affect Sanofi's financial outlook for 2025
80% confidenceThis transaction and the attractive value it brings serves the best interests of the Company and its shareholders
80% confidence
